GENE ONLINE|News &
Opinion
Blog

CRISPR Therapeutics
Trials & Approvals CRISPR Genome Editing
Groundbreaking CRISPR/Cas9-based Genome Editing Therapy Secured the Second FDA Approval
2024-01-18
Trials & Approvals CRISPR-CAS9
FDA Approves A CRISPR-Based Therapy for Sickle Cell Disease
2023-12-12
Editors' Picks weekly highlights
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Trials & Approvals Type 1 Diabetes
Canadian Regulators Give Go-Ahead for Diabetes Trial Using CRISPR, ViaCyte’s Gene-Edited Stem Cell-Derived Therapy
2021-11-16
Startups AAV
Setting its Sights on Neurological Disorders, CRISPR Therapeutics Turns to an AAV Startup That Just Emerged Out of Stealth
2021-06-16
Technology CRISPR
Vertex to Reap Majority Profits from Gene Editing Deal with CRISPR Therapeutics
2021-04-21
Ranking & Reports Gene Therapy
10 Top Gene Therapy Companies in 2021
2021-03-26
Technology CRISPR
CRISPR Therapeutics Scores Prestigious Grant for Advancing Gene Therapies for HIV
2020-12-16
Technology
CRISPR Gene-Edited Therapy CTX001 Raises Hopes for Sickle Cell Disease and β-Thalassemia Cures
2020-12-07
R&D CRISPR
CRISPR Therapeutics’ CAR-T Cell Therapy Registers Mixed Results in Cancer Trial
2020-10-23
Trials & Approvals CRISPR
CRISPR, Vertex’s Gene Editing Based Therapy, CTX001 Prospers in Hemoglobinopathy Trials
2020-06-18
Ranking & Reports CRISPR
GeneOnline’s Top Ten Headlines of the Year
2019-12-30
R&D
Gene Editing Companies to Exchange Patented Tech to Develop Cancer Therapies
2019-10-28
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top